Autoimmune Gastritis: Diagnosis and Management
Diagnose autoimmune gastritis through histopathologic confirmation of corpus-predominant atrophic gastritis combined with serologic testing for antiparietal cell and anti-intrinsic factor antibodies, then manage with vitamin B-12 and iron supplementation, H. pylori testing/treatment, screening for associated autoimmune conditions, and endoscopic surveillance for neuroendocrine tumors and gastric cancer.
Diagnostic Approach
Histopathologic Confirmation (Gold Standard)
The diagnosis of autoimmune gastritis must be confirmed by histopathology showing loss of gastric glands in the corpus with chronic inflammation 1. Obtain biopsies from both the gastric body and antrum/incisura, placed in separately labeled jars, to document the corpus-predominant pattern characteristic of autoimmune gastritis 1. The presence of intestinal metaplasia on gastric histology almost invariably implies underlying atrophic gastritis 1.
Endoscopic Features to Recognize
Look for these specific mucosal changes during upper endoscopy 1:
- Pale appearance of gastric mucosa
- Increased visibility of vasculature due to mucosal thinning
- Loss of gastric folds
- Light blue crests and white opaque fields (if intestinal metaplasia present)
These changes are often subtle, so optimize your mucosal evaluation technique 1.
Serologic Testing
In patients with histology compatible with autoimmune gastritis, check antiparietal cell antibodies and anti-intrinsic factor antibodies to assist with diagnosis 1. While these antibodies support the diagnosis, histopathology remains the definitive diagnostic standard 1.
Laboratory Evaluation for Deficiencies
Evaluate for anemia due to vitamin B-12 and iron deficiencies in all patients with suspected or confirmed autoimmune gastritis 1. The corpus atrophy leads to loss of parietal cells, resulting in impaired intrinsic factor production (B-12 malabsorption) and reduced gastric acid (iron malabsorption).
Management Strategy
Micronutrient Replacement
Provide adequate iron and vitamin B-12 supplementation to all patients with autoimmune gastritis, particularly those with corpus-predominant disease 1, 2. This addresses the primary clinical consequences of parietal cell loss and prevents progression to pernicious anemia.
H. pylori Assessment and Treatment
All individuals with atrophic gastritis, including autoimmune gastritis, should be assessed for H. pylori infection 1. If positive, administer H. pylori treatment and confirm successful eradication using non-serological testing modalities 1. This is critical because concurrent H. pylori infection can complicate the clinical picture and contribute to gastric cancer risk.
Screen for Associated Autoimmune Conditions
Screen for autoimmune thyroid disease in all patients with autoimmune gastritis, as concomitant autoimmune disorders are common, occurring in up to one-third of patients 1. Also consider screening for type 1 diabetes mellitus and other autoimmune conditions 2.
Endoscopic Surveillance Protocol
For Neuroendocrine Tumors
Screen individuals with autoimmune gastritis for type 1 gastric neuroendocrine tumors with upper endoscopy 1. Small neuroendocrine tumors should be removed endoscopically, followed by surveillance endoscopy every 1-2 years depending on tumor burden 1.
For Gastric Cancer Risk
The optimal surveillance interval for autoimmune gastritis is not well-defined and should be based on individualized assessment 1. However, consider surveillance endoscopy every 3 years in individuals with advanced atrophic gastritis based on anatomic extent and histologic grade 1.
Special Consideration: Pernicious Anemia
Recognize pernicious anemia as a late-stage manifestation of autoimmune gastritis characterized by vitamin B-12 deficiency and macrocytic anemia 1. Patients with newly diagnosed pernicious anemia who have not had recent endoscopy should undergo upper endoscopy with topographical biopsies to confirm corpus-predominant atrophic gastritis, risk stratify, and rule out prevalent gastric neoplasia including neuroendocrine tumors 1.
Common Pitfalls to Avoid
Do not rely on serologic testing alone—histopathologic confirmation is mandatory for diagnosis 1. Seronegative autoimmune gastritis exists and can be missed if you depend solely on antibody testing 3.
Do not assume all atrophic gastritis is H. pylori-related—autoimmune gastritis has a distinct corpus-predominant pattern, while H. pylori typically causes antral or multifocal atrophy 1. This is why separate body and antral biopsies are essential.
Do not overlook the increased cancer risk—autoimmune gastritis carries risk for both type 1 neuroendocrine tumors (2.8% incidence per person-year) and gastric adenocarcinoma (0.5% incidence per person-year) 4. Surveillance is not optional.
Do not forget to check for micronutrient deficiencies even in asymptomatic patients—iron and B-12 deficiency can develop before clinical symptoms appear and lead to significant morbidity if untreated 1, 2.
The 2021 AGA Clinical Practice Update 1 provides the most authoritative framework for managing this condition in the United States, emphasizing the importance of histopathologic diagnosis, comprehensive nutritional assessment, and risk-stratified surveillance to prevent the serious complications of gastric neoplasia and micronutrient deficiency.